Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since May 13 · below the Ichimoku cloud · RSI 53 · MACD above its signal · 8% below its 52-week high
None of the 29 investors followed here reported a position in MKGAF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MKGAF trade in the reports read so far (1,238 of 1,240; the rest are being read now).
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for MKGAF.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.6 | 1.9 | -20.7 | 8.5 | 16.5 | 9.9 | -0.6 | -4.1 | 1.2 | -1.7 | +9.2% | ||
| 2025 | 1.1 | -5.2 | -2.6 | -0.3 | -3.9 | -3.1 | -3.1 | -2.7 | 5.5 | 5.7 | -5.4 | 13.1 | −2.6% |
| 2024 | 0.8 | 4.8 | 4.0 | -8.9 | 14.4 | -9.0 | 11.1 | 7.8 | -12.3 | -8.2 | -10.4 | 4.7 | −5.9% |
| 2023 | 7.7 | -8.8 | 0.0 | -5.2 | -4.1 | -4.6 | 6.6 | 2.0 | -8.0 | -8.2 | 13.5 | -6.9 | −17.4% |
| 2022 | -14.9 | -10.1 | 7.2 | -11.6 | -1.0 | -9.6 | 13.1 | -8.7 | -5.9 | 2.8 | 9.2 | 5.4 | −25.4% |
| 2021 | -0.6 | -3.4 | 3.7 | 4.7 | 1.4 | 4.4 | 12.2 | 14.4 | -8.1 | 7.1 | 5.6 | 4.2 | +53.6% |
| 2020 | 10.6 | -5.0 | -14.9 | 8.0 | -4.0 | 6.5 | 9.1 | 8.0 | 8.1 | 0.5 | 7.7 | 7.1 | +46.1% |
| 2019 | 2.4 | -2.1 | 11.2 | -7.3 | -8.4 | 7.3 | 2.8 | 0.1 | 5.8 | 4.8 | -2.2 | 0.6 | +14.2% |
| 2018 | 2.3 | -10.3 | -3.4 | 1.3 | 4.6 | -6.1 | 7.3 | 2.2 | -0.6 | -1.1 | 5.9 | -6.5 | −5.8% |
| 2017 | 3.6 | -0.0 | 4.1 | 3.6 | 1.6 | 3.3 | -10.6 | -0.9 | 5.8 | -7.6 | -0.3 | 1.6 | +2.8% |
| 2016 | -7.6 | -5.3 | -2.2 | 7.5 | 12.1 | 1.4 | 6.0 | -2.5 | 4.6 | -7.0 | -1.9 | 5.4 | +8.6% |
| 2015 | 4.7 | 2.1 | 10.7 | -3.8 | -1.4 | -5.5 | 0.6 | -6.4 | -8.2 | 9.3 | 3.4 | -2.1 | +1.5% |
| 2014 | -13.8 | 6.0 | -2.3 | 1.8 | 5.5 | 0.2 | 0.0 | -1.9 | 7.7 | -1.7 | 8.7 | -2.5 | +5.7% |
| 2013 | 0.0 | 0.0 | 0.0 | 20.3 | 3.3 | 1.4 | 0.0 | 0.0 | -6.7 | 0.5 | 14.5 | 5.4 | +42.5% |
| 2012 | 0.0 | 0.0 | 24.5 | 0.0 | +24.5% |
No analyst coverage for this instrument.
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.